LPTX Stock Risk & Deep Value Analysis

LPTX

Healthcare • Biotechnology

DVR Score

2.6

out of 10

Risk Trap

The Bottom Line on LPTX

We analyzed LPTX using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran LPTX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Mar 15, 2026•Run Fresh Analysis →

📈LPTX Performance Overview3yr weekly

📊

Unlock LPTX Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

LPTX Stock Risk Analysis

Overall Risk

Aggressive

Financial Risk

High

Market Risk

High

About LPTX (LPTX)

Sector

Healthcare

Industry

Biotechnology

Market Cap Category

small

Market Cap

$62.88M

LPTX Deep Value Analysis

Leap Therapeutics (LPTX) maintains a highly speculative 26/100 score, signaling extreme risk but also potential for significant upside if its lead asset, DKN-01, achieves breakthrough clinical success. This score is consistent with the previous analysis from 2026-01-25, as no material changes in fundamentals or major strategic announcements have occurred in the intervening 49 days. The company's future remains almost entirely tied to positive Phase 2 clinical trial readouts for DKN-01 in gastric/GEJ cancers. While the oncology market opportunity is substantial, and DKN-01 targets an unmet need, competitive advantages are nascent, relying solely on eventual clinical validation. Financial health continues to be a critical concern due to ongoing burn, necessitating further dilutive financing. Without a definitive efficacy inflection point, the path to sustainable value creation remains extremely challenging for this micro-cap biotech.

LPTX Red Flags & Warning Signs

⚠
Negative or inconclusive DKN-01 clinical trial results (Q2/Q3 2026)
⚠
Failure to secure adequate financing, leading to further significant dilution or operational slowdowns
⚠
Regulatory delays or adverse outcomes for DKN-01

Unlock LPTX Red Flags & Risk Warnings

Create a free account to see the full analysis

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

LPTX Financial Health Metrics

Market Cap

$62.88M

LPTX Competitive Moat Analysis

Moat Rating

None

Moat Trend

Stable

Moat Sources

1 Identified

Intangible Assets/IP

The primary potential 'moat' lies solely in the intellectual property (patents) surrounding DKN-01. However, this IP does not constitute a durable moat until the drug demonstrates significant clinical efficacy and receives regulatory approval, establishing a clear market advantage and competitive barrier. Without this, the IP alone offers limited protection.

LPTX Competitive Moat Analysis

LPTX Catalysts & Growth Drivers

Near-Term (0-6 months)

•DKN-01 Phase 2 clinical data readout for Gastric/GEJ Cancer (Expected Q2/Q3 2026)
•Updates on financing activities and cash runway extension (Ongoing)

Medium-Term (6-18 months)

•Potential initiation of Phase 3 trials for DKN-01 (Dependent on Phase 2 success)
•Expanded strategic partnerships or licensing agreements for DKN-01 outside current territories

Long-Term (18+ months)

•Regulatory submission and potential approval of DKN-01 in target indications
•Pipeline expansion with new preclinical or early-stage assets

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

LPTX Bull Case: What Could Go Right

✓
Clear, positive efficacy and safety data from DKN-01 Phase 2 trials
✓
Successful non-dilutive financing or significant partnership milestones
✓
Increased institutional ownership or analyst upgrades post-catalyst

Bull Case Analysis

See what could go right with Premium

🔔

Never miss a move on LPTX

Create a free account to set price alerts and get notified on Telegram when LPTX hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for LPTX (LPTX)?

As of March 15, 2026, LPTX has a DVR Score of 2.6 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of LPTX?

LPTX's market capitalization is approximately $62.9M. The company operates in the Healthcare sector within the Biotechnology industry.

What ticker symbol does LPTX use?

LPTX is the ticker symbol for LPTX. The company trades on the NCM.

What is the risk level for LPTX stock?

Our analysis rates LPTX's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

How often is the LPTX DVR analysis updated?

Our AI-powered analysis of LPTX is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 15, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.